Expert Interview
A Second Look: Discussing the recent FDA approval of Madrigal Pharma's Rezdiffra, a liver-directed oral therapy that is designed to target key underlying causes of NASH/MASH
Ticker(s): MDGLInstitution: Southern California Liver Centers
- Hepatologist at Southern California Liver Centers ; formerly Professor of Medicine and Chief of Hepatology at Emory University.
- Currently treats 247 patients with NASH
- Has served on an FDA advisory board evaluating new drugs for hepatology and is actively involved in a number of research studies, including the treatment of hepatitis C and B and non-alcoholic steatohepatitis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
